Shreeji Pharma International manufactures Favipiravir Powder, a highly selective and potent antiviral agent used to inhibit RNA-dependent RNA polymerase in viral infections. Among its effects are those on influenza, SARS-CoV-2, and a range of other viruses.
Applications Or where it is used:
Japan has approved favipiravir for the treatment of influenza. Although it is indicated specifically for novel influenza, it is not indicated for seasonal influenza.
How to use:
Favipiravir Use in COVID-19: A review of potential adverse drug events reported in the WHO database.
Dosage of usage:
Taking favipiravir each day, with or without food, is the recommended regimen. Taking Favipiravir tablets whole is best. Avoid opening, crushing, or chewing the tablets. In patients with COVID-19, the usual dosage of favipiravir is 1800 mg twice daily for the first day and 800 mg twice daily for the following 14 days.
Favipiravir side effects can include swelling and muscle pain all over the body, miscarriages, asthma attacks, gastrointestinal disturbances, hay fever, and allergic dermatitis.
Pregnant women are advised not to use favipiravir because fetal damage may occur.
Warnings and precautions while using this product:
When studied in animals, favipiravir causes mainly early embryonic death. Therefore, it must be avoided during pregnancy. Contraception should be taken during treatment with the most effective method. Treatment should be stopped immediately in case of pregnancy. Favipiravir should not be given to children. It should not be consumed by any patient with a history of hypersensitivity. Influenza-like symptoms should only be treated with this drug. The use of Favipiravir should be examined before it is used.